Welcome to our dedicated page for Xtant Medical news (Ticker: XTNT), a resource for investors and traders seeking the latest updates and insights on Xtant Medical stock.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) is a global medical technology company focused on surgical solutions for spinal, orthopedic, and wound care disorders, with a portfolio centered on orthobiologics and spinal implant systems. The XTNT news feed on Stock Titan aggregates company-issued updates and regulatory disclosures so readers can follow how Xtant communicates its strategy, product launches, and financial performance.
Recent news releases describe Xtant’s emphasis on its core biologics business and regenerative medicine capabilities. The company has announced the commercial launch of products such as CollagenX™, a bovine collagen particulate product for surgical wound closure, and OsteoFactor Pro™, a growth factor-based biologic designed to improve bone healing across orthopedic and spine procedures. Xtant has also introduced Trivium™, a next-generation demineralized bone matrix allograft, and nanOss Strata™, a synthetic bone graft manufactured from hydroxycarbonapatite and designed to mimic human bone structure and support osteoconductivity and cellular activity.
Company news also covers strategic transactions and portfolio changes. Xtant has reported entering into, and subsequently completing, the sale of certain non-core Coflex and CoFix spinal implant assets and its Paradigm Spine GmbH international hardware business to Companion Spine entities, describing these divestitures as a way to sharpen its focus on biologics and strengthen its balance sheet.
Investors and analysts following XTNT news will find quarterly earnings announcements, including revenue trends, gross margin, net income, adjusted EBITDA, and cash flow metrics, as well as financial guidance for the year. The company also issues notices about participation in investor conferences, annual meeting details, and governance developments such as changes to its Board of Directors and amendments to equity incentive plans.
By reviewing the XTNT news stream, readers can see how Xtant presents its mission of honoring the gift of donation, its product development priorities in orthobiologics and wound closure, and the financial and strategic milestones it reports through press releases and SEC-related communications.
Xtant Medical Holdings (NYSE American: XTNT), a global medical technology company specializing in spinal disorder treatments, has announced a $5.0 million private placement of common stock. The company will issue 7,812,500 shares at $0.64 per share to an existing institutional investor. The proceeds will be used for working capital and general corporate purposes.
The private placement is expected to close around August 9, 2024, subject to customary conditions. Craig-Hallum Capital Group is acting as the sole placement agent. The transaction is being conducted under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. Xtant Medical has agreed to file a registration statement with the SEC for the resale of the issued shares.
Xtant Medical Holdings (NYSE American: XTNT), a global medical technology company specializing in surgical solutions for spinal disorders, has announced its upcoming second quarter 2024 financial results release and earnings conference call. The company will disclose its financial results for the quarter ended June 30, 2024, after market close on Thursday, August 8, 2024.
A conference call to discuss the results is scheduled for Friday, August 9, 2024, at 9:00 AM ET. The call will be hosted by Sean Browne, President and CEO, and Scott Neils, CFO. Investors can join via phone or webcast, with replay available on the company's website post-call.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) reported strong financial results for Q2 2024, with revenue increasing 48% to $29.9 million. The company's gross margin improved by 50 basis points to 62.1%. Despite a net loss of $3.9 million, Xtant achieved positive Adjusted EBITDA of $0.5 million.
Key highlights include the launch of two new amniotic membrane allograft products, signing 15 new distributors, and securing 20 IDN contracts. The company also entered a $5.0 million private placement to strengthen its balance sheet.
Xtant reaffirmed its 2024 revenue guidance of $116-$120 million, projecting 27-31% annual growth. The company expects continued momentum with new product launches, increased distributor penetration, and improved margins in the second half of 2024.
Xtant Medical Holdings (NYSE American: XTNT), a global medical technology company specializing in spinal disorder treatments, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase. The event will take place from August 13-15, 2024 at the InterContinental Boston.
Sean Browne, President and CEO, and Scott Neils, CFO, will represent Xtant Medical at the conference. Browne is scheduled to present on Wednesday, August 14th at 11:00 a.m. Eastern. Investors and interested parties can access a video webcast of the presentation through the provided link.
This conference participation offers Xtant Medical an opportunity to showcase its surgical solutions and connect with potential investors and industry professionals.
Xtant Medical, a global medical technology company specializing in spinal disorder treatments, will participate in the 21st Annual Craig-Hallum Institutional Investor Conference on May 29, 2024, in Minneapolis. CEO Sean Browne and CFO Scott Neils will represent the company. The event, featuring over 130 public companies, includes one-on-one and small group meetings. Interested parties can schedule a meeting by contacting Brett Maas or their Craig Hallum representative. Additionally, the company's investor presentation is available on Xtant Medical's investor relations website.
Xtant Medical (NYSE American:XTNT) reported a 55% revenue increase for Q1 2024, reaching $27.9 million compared to $17.9 million in Q1 2023. The growth was driven by acquisitions and increased sales of Coflex and CoFix products.
Gross margin improved to 62.1%, up from 58.7% in the prior year. However, the company recorded a net loss of $4.3 million, higher than the $2.1 million loss in Q1 2023. Adjusted EBITDA turned positive at $0.1 million from a loss of $0.3 million in the previous year.
Xtant launched two new amniotic membrane allografts and amended credit agreements for more working capital. The company raised its 2024 revenue guidance to $116 million - $120 million, indicating a 27%-31% growth compared to 2023.
Apyx Medical announced the retirement of Andrew Makrides as Chairman of the Board, who served the company since 1982, and the appointment of Stavros Vizirgianakis as the new Chairman. Makrides contributed to the company's growth over the years, while Vizirgianakis brings extensive medical device industry experience to the role.
Xtant Medical Holdings, Inc. (NYSE American:XTNT) will release its first quarter 2024 financial results on May 15, 2024. The global medical technology company specializing in spinal disorder surgical solutions will have a conference call hosted by President Sean Browne and CFO Scott Neils at 4:30 PM ET on the same day. Details can be accessed through the provided conference dial-in or webcast link.
Xtant Medical Holdings, Inc. announced the full commercial launch of two amniotic membrane allografts, SimpliGraft™ and SimpliMax™, for chronic and acute wounds. The products are dehydrated, terminally irradiated, single and dual-layer amniotic membrane sheets intended to provide protective coverage from the surrounding environment when applied topically. Manufactured at Xtant’s biologics processing center in Belgrade, Montana, the company aims to position itself as a leader and innovator in advanced biologic therapies.
Summary not available.